Skip to main content
Premium Trial:

Request an Annual Quote

Intradigm Develops siRNA SARS Inhibitor

NEW YORK, Sept. 5 (GenomeWeb News) - Intradigm announced today that it had developed siRNA capable of achieving 90 percent inhibition of the SARS virus in cell-based studies.

 

The Rockville, Md.-based RNAi company collaborated with Qiagen to design the siRNA, which targeted specific genes throughout the SARS genome. Qiagen synthesized the siRNA, and the product was tested in laboratories in Hong Kong and Guangzhou, China using non-human primate cells exposed to the SARS virus. Hong Kong-based Top Biotech sponsored the effort along with the provincial government of Guangdong province, China. Scientists from GuangzhouMedicalUniversity and Zhongshan University of Guangzhou, as well as Hong KongUniversity also worked on the project.

 

Intradigm has already established a collaboration with scientists from the National Institute of Allergy and Infectious Diseases in the US, and from institutions in Hong Kong and Guangzhou to develop siRNA-based anti-SARS therapies.

 

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.